NCT06245629 Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma
| NCT ID | NCT06245629 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Uppsala University |
| Condition | Myeloma Multiple |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-11-24 |
| Primary Completion | 2025-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2024-11-24 with a primary completion date of 2025-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This project will evaluate the efficacy and safety of the conditioning regimen bortezomib-bendamustine-melphalan (BBM) in combination with autologous hematopoietic stem cell transplantation (ASCT) in relapsed multiple myeloma given from 2011 to 2018 at Uppsala University Hospital. This approach will be retrospectively compared to high dose melphalan (HDM) in the same setting in the years prior to, and following the BBM-period. Data on efficacy and safety data will be collected through systematic analysis of electronic medical records and from the Swedish Cancer Registry.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of first relapse after previous ASCT for multiple myeloma according to the International Myeloma Working Group. * Treated with a second ASCT (ASCT2) as part of second line treatment at UUH. * Conditioning at ASCT2 with bortezomib-bendamustine-melphalan or high-dose melphalan only. Exclusion Criteria: * Double (tandem) ASCT in first or second line treatment * Allogenic haematopoietic stem cell transplantation as part of first or second line therapy * Failure to meet the minimal dataset, defined as: (date of ASCT1 and ASCT2, date of start of induction treatment for relapsed myeloma prior to ASCT2, medical records from hospitalization for ASCT2, at least one follow-up visit (unless early death before first follow-up visit), date of progression and first treatment of relapsed multiple myeloma after ASCT2.
Contact & Investigator
Honar Cherif, MD, PhD
PRINCIPAL INVESTIGATOR
Uppsala University
Frequently Asked Questions
Who can join the NCT06245629 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Myeloma Multiple. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06245629 currently recruiting?
Yes, NCT06245629 is actively recruiting participants. Contact the research team at thomas.silfverberg@regiondalarna.se for enrollment information.
Where is the NCT06245629 trial being conducted?
This trial is being conducted at Uppsala, Sweden.
Who is sponsoring the NCT06245629 clinical trial?
NCT06245629 is sponsored by Uppsala University. The principal investigator is Honar Cherif, MD, PhD at Uppsala University. The trial plans to enroll 100 participants.